WAY 170523

MMP-13 inhibitor,potent and selective CAS# 307002-73-9

WAY 170523

Catalog No. BCC2380----Order now to get a substantial discount!

Product Name & Size Price Stock
WAY 170523: 5mg $794 In Stock
WAY 170523: 10mg Please Inquire In Stock
WAY 170523: 20mg Please Inquire Please Inquire
WAY 170523: 50mg Please Inquire Please Inquire
WAY 170523: 100mg Please Inquire Please Inquire
WAY 170523: 200mg Please Inquire Please Inquire
WAY 170523: 500mg Please Inquire Please Inquire
WAY 170523: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of WAY 170523

Number of papers citing our products

Chemical structure

WAY 170523

3D structure

Chemical Properties of WAY 170523

Cas No. 307002-73-9 SDF Download SDF
PubChem ID 9830392 Appearance Powder
Formula C33H31N3O7S M.Wt 613.68
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO > 10 mM
Chemical Name N-[2-[4-[benzyl-[2-(hydroxycarbamoyl)-4,6-dimethylphenyl]sulfamoyl]phenoxy]ethyl]-1-benzofuran-2-carboxamide
SMILES CC1=CC(=C(C(=C1)C(=O)NO)N(CC2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)OCCNC(=O)C4=CC5=CC=CC=C5O4)C
Standard InChIKey FARMEEAGJWMFSZ-UHFFFAOYSA-N
Standard InChI InChI=1S/C33H31N3O7S/c1-22-18-23(2)31(28(19-22)32(37)35-39)36(21-24-8-4-3-5-9-24)44(40,41)27-14-12-26(13-15-27)42-17-16-34-33(38)30-20-25-10-6-7-11-29(25)43-30/h3-15,18-20,39H,16-17,21H2,1-2H3,(H,34,38)(H,35,37)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of WAY 170523

DescriptionPotent and selective inhibitor of MMP-13 (IC50 values are 17, 945, > 1000 and > 10000 nM for MMP-13, MMP-9, TACE and MMP-1 respectively).

WAY 170523 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

WAY 170523 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of WAY 170523

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.6295 mL 8.1476 mL 16.2951 mL 32.5903 mL 40.7378 mL
5 mM 0.3259 mL 1.6295 mL 3.259 mL 6.5181 mL 8.1476 mL
10 mM 0.163 mL 0.8148 mL 1.6295 mL 3.259 mL 4.0738 mL
50 mM 0.0326 mL 0.163 mL 0.3259 mL 0.6518 mL 0.8148 mL
100 mM 0.0163 mL 0.0815 mL 0.163 mL 0.3259 mL 0.4074 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on WAY 170523

Description:IC50: 17 nm (MMP-13)
Collagenase 3 is an enzyme that in humans is encoded by the MMP13 gene. Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis .
In vitro: The combination of NMR spectroscopy with molecular modeling techniques and HTS data resulted in the design of a novel, potent, and selective MMP-13 inhibitor (WAY-170523) which has an IC50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivity against MMP-1, MMP-9, and TACE, respectively. To the best of our knowledge, this represents the first example of a potent MMP-13 inhibitor that has been shown to be selective against MMP-9 [1].
In vivo: In order to investigate a putative role of MMP-13 in ISO-dependent cardiac dysfunction, the authors infused WT mice with ISO for 7 days and concurrently delivered the specific MMP-13 inhibitor WAY170523 daily by i.p injection. Remarkably, they found that WAY170523 completely abolished ISO-dependent increase of the left ventricular systolic diameter and preserved cardiac function in ISO-infused animals without modifying the hypertrophic response similar to the PAR1 KO animals. [2].
Clinical trial: WAY-170523 is currently in the preclinical development and no clinical trial is ongoing.
References:
[1] James M. Chen, Frances C. Nelson, Jeremy I. Levin, Dominick Mobilio, Franklin J. Moy, Ramaswamy Nilakantan, Arie Zask, and Robert Powers. Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design. J. Am. Chem. Soc. 2000, 122, 9648-9654
[2] Jaffré F, Friedman AE, Hu Z, Mackman N, Blaxall BC. β-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation. 2012;125(24):2993-3003.

Featured Products
New Products
 

References on WAY 170523

The problem of choice: From the voluntary way to Affordable Care Act health insurance exchanges.[Pubmed:28371627]

Soc Sci Med. 2017 May;181:34-42.

This article takes a genealogical and ethnographic approach to the problem of choice, arguing that what choice means has been reworked several times since health insurance first figured prominently in national debates about health reform. Whereas voluntary choice of doctor and hospital used to be framed as an American right, contemporary choice rhetoric includes consumer choice of insurance plan. Understanding who has deployed choice rhetoric and to what ends helps explain how offering choices has become the common sense justification for defending and preserving the exclusionary health care system in the United States. Four case studies derived from 180 enrollment observations at the Rhode Island health insurance exchange conducted from March 2014-January 2017 and interviews with enrollees show how choice is experienced in this latest iteration of health reform. The Affordable Care Act (ACA) of 2010 created new pathways to insurance coverage in the United States. Insurance exchanges were supposed to unleash the power of consumer decision-making through marketplaces where health plans compete on quality, coverage, and price. Consumers, however, contended with confusing insurance terminology and difficult to navigate websites. The ethnography shows that consumers experienced choice as confusing and overwhelming and did not feel "in charge" of their decisions. Instead, unstable employment, changes in income, existing health needs, and bureaucratic barriers shaped their "choices."

DNA Three-Way Junction for Differentiation of Single-Nucleotide Polymorphisms with Fluorescent Copper Nanoparticles.[Pubmed:28370648]

Chemistry. 2017 May 23;23(29):6979-6982.

A label- and enzyme-free fluorescent sensor for the detection of single-nucleotide polymorphisms (SNPs) at room temperature is proposed, using new copper nanoparticles (CuNPs) as fluorescent reporters. The CuNPs were constructed by using a DNA three-way junction (3WJ) template. In this assay, two complementary adenine/thymine-rich probes can hybridize with the wild-type target simultaneously to construct a 3WJ structure, serving as an efficient scaffold for the generation of CuNPs. However, the CuNPs produce weak fluorescence when the probes bind with a mutant-type target. SNPs can be identified by the difference in fluorescence intensity of the CuNPs. This SNPs detection strategy is straightforward, cost-effective, and avoids the complicated procedures of labeling or enzymatic reactions. The fluorescent sensor is versatile and can be applied to all types of mutation because the probes are programmable. Moreover, the sensor exhibits good detection performance in biological samples.

Keywords:

WAY 170523,307002-73-9,Natural Products,MMP, buy WAY 170523 , WAY 170523 supplier , purchase WAY 170523 , WAY 170523 cost , WAY 170523 manufacturer , order WAY 170523 , high purity WAY 170523

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: